Cue Biopharma raises $50M in private placement led by Cormorant and Columbia Threadneedle

Cue Biopharma, Inc.

Gross proceeds of $50M from sale of 1,418,071 shares at $33.21/share and pre-funded warrants for 87,500 shares at $33.209.
Private placement led by Cormorant Asset Management and Columbia Threadneedle Investments; expected to close July 13, 2026.
Net proceeds to fund clinical development and general corporate purposes; CEO cites upcoming Phase 2 CSU data from Ascendant Health expected by Q3 2026.
Board granted 1,064,492 RSUs to employees and executives, including 655,074 RSUs to CEO Shao-Lee Lin, with time and performance-based vesting.

item 1.01 item 3.02 item 5.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.